Q-omics provides the consensus-scored RPL27AP8 profile across patient tissues and cancer cell-line models. RPL27AP8 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPL27AP8 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, RPL27AP8 RNA expression shows 4,097 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight CESC, COAD, and BRCA as cancer lineages where RPL27AP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL27AP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL27AP8 survival associations across molecular data types. RPL27AP8 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL27AP8 RNA expression–survival associations across cancer types. High RPL27AP8 expression shows unfavorable associations in KICH, PAAD, MESO and UVM, but favorable associations in CESC and UCS. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for RPL27AP8 RNA expression.
This table summarizes RPL27AP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL27AP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL27AP8 shows higher tumor expression in COAD and LIHC. The COAD box plot shows higher RPL27AP8 RNA expression in tumor versus normal tissue (log2 FC = +0.177, t-test p = .003).
This table shows molecular features associated with RPL27AP8 in patient tissues and cancer cell lines. In patient samples, RPL27AP8 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
